Table 5.
In-hospital mortality | 30-day mortality | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Bivariate | Multivariable | Bivariate | Multivariable | |||||||
Alive | Dead | p value | HR (95% CI) | p value | Alive | Dead | p value | HR (95% CI) | p value | |
Natremia levels | <0.001 | |||||||||
Normal | 2,560 (68.2) | 138 (50.2) | 1 (reference) | 2,473 (68.5) | 225 (53.2) | <0.001 | 1 (reference) | |||
Decreased | 1,196 (31.8) | 137 (49.8) | 1.82 (1.43–2.33) | <0.001 | 1,135 (31.5) | 198 (46.8) | 1.68 (1.37–2.04) | <0.001 | ||
Natremia levels | <0.001 | |||||||||
Normal | 2,560 (68.2) | 138 (50.2) | 1 (reference) | 2,473 (68.5) | 225 (53.2) | <0.001 | 1 (reference) | |||
Mild (130–135 mEq/L) | 825 (22) | 78 (28.4) | 1.48 (1.12–1.97) | 0.007 | 792 (22.0) | 111 (26.2) | 1.34 (1.06–1.69) | 0.013 | ||
Moderate (125–129 mEq/L) | 230 (6.1) | 38 (13.8) | 2.54 (1.75–3.67) | <0.001 | 209 (5.8) | 59 (14.0) | 2.52 (1.88–3.39) | <0.001 | ||
Severe (<125 mEq/L) | 141 (3.8) | 21 (7.6) | 3.00 (1.88–4.79) | <0.001 | 134 (3.7) | 28 (6.6) | 2.47 (1.65–3.69) | <0.001 | ||
p value for trend | <0.001 | <0.001 | ||||||||
Persistent hyponatremia | <0.001 | |||||||||
Normal | 2,560 (68.2) | 138 (50.2) | 1 (reference) | 2,473 (68.5) | 225 (53.2) | 1 (reference) | ||||
Non-persistent | 797 (21.2) | 77 (28.0) | 1.57 (1.18–2.09) | 0.002 | 767 (21.3) | 107 (25.3) | 1.39 (1.09–1.76) | 0.007 | ||
Persistent | 399 (10.6) | 60 (21.8) | 2.29 (1.68–3.12) | <0.001 | 368 (10.2) | 91 (21.5) | 2.20 (1.72–2.83) | <0.001 | ||
p value for trend‡ | <0.001 | <0.001 |
HR, hazard ratio; CI, confidence interval.
Multivariable model.
Results are expressed as number (column percentage) for bivariate comparisons and as multivariable-adjusted odds ratio and (95% confidence interval) for multivariable comparisons. Between-group comparisons performed using chi-square (bivariate) and Cox regression (multivariable). Multivariable analyses were performed adjusting for age (four categories), gender, main cause for hospitalization (eight categories), and number of associated comorbidities.